Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ011133 plus toripalimab in advanced solid tumors
CTR20212898Phase 2Terminated
- Sponsor
- Tianjing Biopharma
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lemzoparlimab in Nonhematologic neoplasms, melanoma, gastric cancer (GC), head and neck squamous cell carcinoma (HNSCC), sponsored by Tianjing Biopharma. Started Nov 2021; status: terminated.
02
Drugs
lemzoparlimab
03
Conditions
Nonhematologic neoplasmsmelanomagastric cancer (GC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20212898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212898.